WO2002058686A3 - Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes - Google Patents

Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes Download PDF

Info

Publication number
WO2002058686A3
WO2002058686A3 PCT/US2002/002108 US0202108W WO02058686A3 WO 2002058686 A3 WO2002058686 A3 WO 2002058686A3 US 0202108 W US0202108 W US 0202108W WO 02058686 A3 WO02058686 A3 WO 02058686A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
neurodegenerative disorders
pentaaza
ligand complexes
macrocyclic ligand
Prior art date
Application number
PCT/US2002/002108
Other languages
French (fr)
Other versions
WO2002058686A2 (en
Inventor
Daniela Salvemini
Dennis P Riley
Original Assignee
Metaphore Pharmaceuticals Inc
Daniela Salvemini
Dennis P Riley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metaphore Pharmaceuticals Inc, Daniela Salvemini, Dennis P Riley filed Critical Metaphore Pharmaceuticals Inc
Priority to EP02703228A priority Critical patent/EP1353655A2/en
Priority to AU2002236861A priority patent/AU2002236861A1/en
Publication of WO2002058686A2 publication Critical patent/WO2002058686A2/en
Publication of WO2002058686A3 publication Critical patent/WO2002058686A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to pharmaceutical compositions and methods using such compositions for the treatment of neurodegenerative disorders. Such compositions contain a catalyst for the dismutation of superoxide, including superoxide dismutase enzyme (SOD) and low molecular weight organic ligand derived metal complexes that function as mimics of the enzyme (SOD mimetics or SODms).
PCT/US2002/002108 2001-01-26 2002-01-23 Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes WO2002058686A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02703228A EP1353655A2 (en) 2001-01-26 2002-01-23 Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
AU2002236861A AU2002236861A1 (en) 2001-01-26 2002-01-23 Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26449301P 2001-01-26 2001-01-26
US60/264,493 2001-01-26

Publications (2)

Publication Number Publication Date
WO2002058686A2 WO2002058686A2 (en) 2002-08-01
WO2002058686A3 true WO2002058686A3 (en) 2003-02-06

Family

ID=23006301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/002108 WO2002058686A2 (en) 2001-01-26 2002-01-23 Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes

Country Status (3)

Country Link
EP (1) EP1353655A2 (en)
AU (1) AU2002236861A1 (en)
WO (1) WO2002058686A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20040124A1 (en) 2004-03-01 2004-06-01 Medestea Internaz Srl NEW USES IN THERAPY OF N-PIPERIDINE DERIVATIVES PARTICULARLY FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES
EP2056675B1 (en) 2006-10-12 2019-01-09 Galera Labs, LLC Methods of treating oral mucositis
US9149483B2 (en) 2011-09-26 2015-10-06 Galera Labs, Llc Methods for treatment of diseases
DK3334744T3 (en) 2015-08-11 2020-07-27 Galera Labs Llc MACROCYCLIC PENTAAZA RING COMPLEX WITH ORAL BIO ACCESSIBILITY
WO2018098484A1 (en) 2016-11-28 2018-05-31 Texas Tech University System Drug targets of delayed aging and human brain diseases
CA3053779A1 (en) * 2017-02-15 2018-08-23 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local intestinal delivery
IL295620B2 (en) 2017-04-13 2024-01-01 Galera Labs Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
JP2022551494A (en) * 2019-10-10 2022-12-09 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー Aqueous formulations of manganese-containing coordination complexes, formulations and treatment methods

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0524161A1 (en) * 1991-07-19 1993-01-20 Monsanto Company Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1995010185A1 (en) * 1993-10-15 1995-04-20 Duke University Superoxide dismutase and mimetics thereof
US5426122A (en) * 1989-03-17 1995-06-20 Cedars-Sinai Medical Center Methods for reducing blood pressure with dimercaptosuccinic acid (DMSA)
WO1996040148A1 (en) * 1995-06-07 1996-12-19 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
WO1997033588A1 (en) * 1996-03-13 1997-09-18 Monsanto Company Iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1998058636A1 (en) * 1997-06-20 1998-12-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
WO1999037616A1 (en) * 1998-01-22 1999-07-29 Aenggaard Erik Emil Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress
WO2000028041A1 (en) * 1998-11-05 2000-05-18 Microbiological Research Authority Delivery of superoxide dismutase to neuronal cells
WO2001019823A2 (en) * 1999-09-16 2001-03-22 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426122A (en) * 1989-03-17 1995-06-20 Cedars-Sinai Medical Center Methods for reducing blood pressure with dimercaptosuccinic acid (DMSA)
EP0524161A1 (en) * 1991-07-19 1993-01-20 Monsanto Company Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1995010185A1 (en) * 1993-10-15 1995-04-20 Duke University Superoxide dismutase and mimetics thereof
WO1996040148A1 (en) * 1995-06-07 1996-12-19 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
WO1997033588A1 (en) * 1996-03-13 1997-09-18 Monsanto Company Iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1998058636A1 (en) * 1997-06-20 1998-12-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
WO1999037616A1 (en) * 1998-01-22 1999-07-29 Aenggaard Erik Emil Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress
WO2000028041A1 (en) * 1998-11-05 2000-05-18 Microbiological Research Authority Delivery of superoxide dismutase to neuronal cells
WO2001019823A2 (en) * 1999-09-16 2001-03-22 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
HENKE S.L.: "Superoxide dismutase mimics as future therapeutics.", EXPERT OPINION ON THERAPEUTIC PATENTS, (1999) 9/2 (169-180)., XP000905307 *
JENNER P.: "Oxidative damage in neurodegenerative disease", THE LANCET, vol. 344, 1994, pages 796 - 798, XP001109113 *
MOLLACE VINCENZO ET AL: "Protective effect of novel free-radical scavengers in HIV-related apoptosis of human cultured astroglial cells.", JOURNAL OF NEUROVIROLOGY, vol. 6, no. 3, June 2000 (2000-06-01), Neuroscience of HIV Infection 2000;Edinburgh, Scotland; June 22-24, 2000, pages 258, XP008010345, ISSN: 1355-0284 *
MOLLACE, NOTTET ET AL.: "Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants", TRENDS IN NEUROSCIENCES, vol. 24, no. 7, June 2001 (2001-06-01), pages 411 - 416, XP002220006 *
MOLLACE, VINCENZO ET AL: "The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages", JOURNAL OF LEUKOCYTE BIOLOGY (2002), 71(1), 65-72, XP008010036 *
NICOLAUS B J R: "Symbiotic Approach to Drug Design", DECISION MAKING IN DRUG RESEARCH, XX, XX, 1983, pages 173 - 186, XP002197412 *
PATEL M: "INHIBITION OF NEURONAL APOPTOSIS BY A METALLOPORPHYRIN SUPEROXIDE DISMUTASE MIMIC", JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 71, no. 3, 1998, pages 1068 - 1074, XP000900559, ISSN: 0022-3042 *
SALVEMINI DANIELA ET AL: "A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats.", SCIENCE (WASHINGTON D C), vol. 286, no. 5438, 8 October 1999 (1999-10-08), pages 304 - 306, XP002220005, ISSN: 0036-8075 *
See also references of EP1353655A2 *

Also Published As

Publication number Publication date
EP1353655A2 (en) 2003-10-22
WO2002058686A2 (en) 2002-08-01
AU2002236861A1 (en) 2002-08-06

Similar Documents

Publication Publication Date Title
AU2002360982A1 (en) Support-fixed bleaching catalyst complex compounds suitable as catalysts for peroxide compounds
IL225203A (en) Isolated complement factor h polypeptide, means for its preparation, uses thereof and an agent that reduces its expression or activity
HK1046689A1 (en) Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity.
WO2007094819A3 (en) Triazole compounds that modulate hsp90 activity
WO2004103960A3 (en) Compounds and uses thereof
AU2182001A (en) Catalysts for hydrosilylation reactions
WO2003053336A3 (en) Methods for the treatment of peripheral neural and vascular ailments
WO2002081651A3 (en) Polyphenolics for enhancing endothelial cell-mediated fibrinolysis
WO2006110588A8 (en) Methods for treating mild cognitive impairment
WO2006085932A3 (en) Anti-viral uses of borinic acid complexes
WO2002060383A3 (en) Cancer therapy
WO2002058686A3 (en) Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2003070204A3 (en) Lipase inhibiting composition
WO2002030357A3 (en) Compounds and methods for modulating ccr4 function
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2003072063A3 (en) Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
WO2004073375A8 (en) Podophyllotoxin derivatives as antitumor agents
WO2005005382A3 (en) Compounds, compositions and methods
WO2003072053A3 (en) Compounds for treatment of copper overload
MXPA03011795A (en) COMBINATION THERAPY OF AN SODm AND A CORTICOSTEROID FOR PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASE.
WO2003017817A3 (en) Diagnosis, prevention and treatment of cancer
WO2002020156A3 (en) Stable catalysts and co-catalyst compositions formed from hydroxyaluminoxane and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002703228

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002703228

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002703228

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP